Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions

Atsuki Fukushima, Tomoko Yamaguchi, Waka Ishida, Kazuyo Fukata, Fu-Tong Liu, Hisayuki Ueno

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Eosinophils are important effector cells in severe allergic conjunctivitis such as vernal keratoconjunctivitis. Infiltration of eosinophils into the conjunctiva is mediated by type I and type IV allergic reactions. Cyclosporin A (CsA) eye drops are administered therapeutically for severe allergic conjunctivitis, but the mechanism by which CsA acts, that is, by inhibiting type I, type IV or both types of allergic reactions, is not known. We investigated whether CsA eye drops inhibit type I, type IV or both types of allergic reactions in the conjunctiva. Methods: Experimental immune-mediated blepharoconjunctivit is (EC) was induced in BALB/c mice by either active immunization or passive immunization by transfer of ragweed (RW)-primed splenocytes and RW-specific IgE, followed by RW challenge to the conjunctiva. These mice were treated in eye drops with vehicle, 0.1% CsA, 0.5% CsA or 0.1% betamethasone five times (1 and 2 h before RW challenge and 1, 2 and 3 h after RW challenge). Twenty-four hours after the challenge, the conjunctivas were harvested for histological analysis to evaluate eosinophilic infiltration. To evaluate effects of CsA eye drops on systemic immune responses, sera and spleens were collected from actively immunized mice at the time of sacrifice to examine serum IgE levels and cellular immune responses, respectively. Results: CsA eye drops significantly inhibited eosinophilic infiltration into the conjunctiva in actively immunized EC-developing mice compared with vehicle-treated mice. The CsA-induced inhibition was similar to inhibition induced by 0.1% betamethasone. Serum IgE levels and splenocyte responses in CsA-treated mice were equivalent to those in vehicle-treated mice. Betamethasone treatment inhibited eosinophilic infiltration into the conjunctiva induced by both splenocyte transfer and IgE transfer, while CsA treatment inhibited infiltration induced by splenocyte transfer. Conclusions: CsA eye drops inhibited eosinophilic infiltration into the conjunctiva without affecting systemic immune responses. CsA predominantly inhibits eosinophilic infiltration by interfering with the type IV allergic reaction in the conjunctiva.

Original languageEnglish (US)
Pages (from-to)347-353
Number of pages7
JournalClinical and Experimental Ophthalmology
Volume34
Issue number4
DOIs
StatePublished - May 2006

Fingerprint

Conjunctiva
Cyclosporine
Hypersensitivity
Ophthalmic Solutions
Ambrosia
Allergic Conjunctivitis
Betamethasone
Immunoglobulin E
Eosinophils
Passive Immunization
Serum
Cellular Immunity
Immune Sera
Vaccination
Spleen

Keywords

  • Betamethasone
  • Cyclosporin A
  • Eosinophil
  • Experimental immune-mediated blepharoconjunctivitis
  • Eye drop

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions. / Fukushima, Atsuki; Yamaguchi, Tomoko; Ishida, Waka; Fukata, Kazuyo; Liu, Fu-Tong; Ueno, Hisayuki.

In: Clinical and Experimental Ophthalmology, Vol. 34, No. 4, 05.2006, p. 347-353.

Research output: Contribution to journalArticle

Fukushima, Atsuki ; Yamaguchi, Tomoko ; Ishida, Waka ; Fukata, Kazuyo ; Liu, Fu-Tong ; Ueno, Hisayuki. / Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions. In: Clinical and Experimental Ophthalmology. 2006 ; Vol. 34, No. 4. pp. 347-353.
@article{d32ea5f7e3a24525a68734cd5666e017,
title = "Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions",
abstract = "Background: Eosinophils are important effector cells in severe allergic conjunctivitis such as vernal keratoconjunctivitis. Infiltration of eosinophils into the conjunctiva is mediated by type I and type IV allergic reactions. Cyclosporin A (CsA) eye drops are administered therapeutically for severe allergic conjunctivitis, but the mechanism by which CsA acts, that is, by inhibiting type I, type IV or both types of allergic reactions, is not known. We investigated whether CsA eye drops inhibit type I, type IV or both types of allergic reactions in the conjunctiva. Methods: Experimental immune-mediated blepharoconjunctivit is (EC) was induced in BALB/c mice by either active immunization or passive immunization by transfer of ragweed (RW)-primed splenocytes and RW-specific IgE, followed by RW challenge to the conjunctiva. These mice were treated in eye drops with vehicle, 0.1{\%} CsA, 0.5{\%} CsA or 0.1{\%} betamethasone five times (1 and 2 h before RW challenge and 1, 2 and 3 h after RW challenge). Twenty-four hours after the challenge, the conjunctivas were harvested for histological analysis to evaluate eosinophilic infiltration. To evaluate effects of CsA eye drops on systemic immune responses, sera and spleens were collected from actively immunized mice at the time of sacrifice to examine serum IgE levels and cellular immune responses, respectively. Results: CsA eye drops significantly inhibited eosinophilic infiltration into the conjunctiva in actively immunized EC-developing mice compared with vehicle-treated mice. The CsA-induced inhibition was similar to inhibition induced by 0.1{\%} betamethasone. Serum IgE levels and splenocyte responses in CsA-treated mice were equivalent to those in vehicle-treated mice. Betamethasone treatment inhibited eosinophilic infiltration into the conjunctiva induced by both splenocyte transfer and IgE transfer, while CsA treatment inhibited infiltration induced by splenocyte transfer. Conclusions: CsA eye drops inhibited eosinophilic infiltration into the conjunctiva without affecting systemic immune responses. CsA predominantly inhibits eosinophilic infiltration by interfering with the type IV allergic reaction in the conjunctiva.",
keywords = "Betamethasone, Cyclosporin A, Eosinophil, Experimental immune-mediated blepharoconjunctivitis, Eye drop",
author = "Atsuki Fukushima and Tomoko Yamaguchi and Waka Ishida and Kazuyo Fukata and Fu-Tong Liu and Hisayuki Ueno",
year = "2006",
month = "5",
doi = "10.1111/j.1442-9071.2006.01221.x",
language = "English (US)",
volume = "34",
pages = "347--353",
journal = "Clinical and Experimental Ophthalmology",
issn = "1442-6404",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions

AU - Fukushima, Atsuki

AU - Yamaguchi, Tomoko

AU - Ishida, Waka

AU - Fukata, Kazuyo

AU - Liu, Fu-Tong

AU - Ueno, Hisayuki

PY - 2006/5

Y1 - 2006/5

N2 - Background: Eosinophils are important effector cells in severe allergic conjunctivitis such as vernal keratoconjunctivitis. Infiltration of eosinophils into the conjunctiva is mediated by type I and type IV allergic reactions. Cyclosporin A (CsA) eye drops are administered therapeutically for severe allergic conjunctivitis, but the mechanism by which CsA acts, that is, by inhibiting type I, type IV or both types of allergic reactions, is not known. We investigated whether CsA eye drops inhibit type I, type IV or both types of allergic reactions in the conjunctiva. Methods: Experimental immune-mediated blepharoconjunctivit is (EC) was induced in BALB/c mice by either active immunization or passive immunization by transfer of ragweed (RW)-primed splenocytes and RW-specific IgE, followed by RW challenge to the conjunctiva. These mice were treated in eye drops with vehicle, 0.1% CsA, 0.5% CsA or 0.1% betamethasone five times (1 and 2 h before RW challenge and 1, 2 and 3 h after RW challenge). Twenty-four hours after the challenge, the conjunctivas were harvested for histological analysis to evaluate eosinophilic infiltration. To evaluate effects of CsA eye drops on systemic immune responses, sera and spleens were collected from actively immunized mice at the time of sacrifice to examine serum IgE levels and cellular immune responses, respectively. Results: CsA eye drops significantly inhibited eosinophilic infiltration into the conjunctiva in actively immunized EC-developing mice compared with vehicle-treated mice. The CsA-induced inhibition was similar to inhibition induced by 0.1% betamethasone. Serum IgE levels and splenocyte responses in CsA-treated mice were equivalent to those in vehicle-treated mice. Betamethasone treatment inhibited eosinophilic infiltration into the conjunctiva induced by both splenocyte transfer and IgE transfer, while CsA treatment inhibited infiltration induced by splenocyte transfer. Conclusions: CsA eye drops inhibited eosinophilic infiltration into the conjunctiva without affecting systemic immune responses. CsA predominantly inhibits eosinophilic infiltration by interfering with the type IV allergic reaction in the conjunctiva.

AB - Background: Eosinophils are important effector cells in severe allergic conjunctivitis such as vernal keratoconjunctivitis. Infiltration of eosinophils into the conjunctiva is mediated by type I and type IV allergic reactions. Cyclosporin A (CsA) eye drops are administered therapeutically for severe allergic conjunctivitis, but the mechanism by which CsA acts, that is, by inhibiting type I, type IV or both types of allergic reactions, is not known. We investigated whether CsA eye drops inhibit type I, type IV or both types of allergic reactions in the conjunctiva. Methods: Experimental immune-mediated blepharoconjunctivit is (EC) was induced in BALB/c mice by either active immunization or passive immunization by transfer of ragweed (RW)-primed splenocytes and RW-specific IgE, followed by RW challenge to the conjunctiva. These mice were treated in eye drops with vehicle, 0.1% CsA, 0.5% CsA or 0.1% betamethasone five times (1 and 2 h before RW challenge and 1, 2 and 3 h after RW challenge). Twenty-four hours after the challenge, the conjunctivas were harvested for histological analysis to evaluate eosinophilic infiltration. To evaluate effects of CsA eye drops on systemic immune responses, sera and spleens were collected from actively immunized mice at the time of sacrifice to examine serum IgE levels and cellular immune responses, respectively. Results: CsA eye drops significantly inhibited eosinophilic infiltration into the conjunctiva in actively immunized EC-developing mice compared with vehicle-treated mice. The CsA-induced inhibition was similar to inhibition induced by 0.1% betamethasone. Serum IgE levels and splenocyte responses in CsA-treated mice were equivalent to those in vehicle-treated mice. Betamethasone treatment inhibited eosinophilic infiltration into the conjunctiva induced by both splenocyte transfer and IgE transfer, while CsA treatment inhibited infiltration induced by splenocyte transfer. Conclusions: CsA eye drops inhibited eosinophilic infiltration into the conjunctiva without affecting systemic immune responses. CsA predominantly inhibits eosinophilic infiltration by interfering with the type IV allergic reaction in the conjunctiva.

KW - Betamethasone

KW - Cyclosporin A

KW - Eosinophil

KW - Experimental immune-mediated blepharoconjunctivitis

KW - Eye drop

UR - http://www.scopus.com/inward/record.url?scp=33746492214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746492214&partnerID=8YFLogxK

U2 - 10.1111/j.1442-9071.2006.01221.x

DO - 10.1111/j.1442-9071.2006.01221.x

M3 - Article

VL - 34

SP - 347

EP - 353

JO - Clinical and Experimental Ophthalmology

JF - Clinical and Experimental Ophthalmology

SN - 1442-6404

IS - 4

ER -